MedTrace Logo

The Role of Paracetamol-caffeine and Laser Irradiation on Controlling Pain and Discomfort During Orthodontic Treatment

NCT03400111 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-07-18

No results posted yet for this study

Summary

Patients with class I malocclusion who have mild to moderate crowding will be treated in this study. The efficacy of low level laser therapy and Panadol-extra® in relieving pain due to orthodontic treatment will be assessed. The effect of these two interventions on oral-health related quality of life during all stages of orthodontic treatment will be explored, i.e. at the following stages: (1) separation between teeth, (2) archwire changing, (3) bonding of brackets, (4) removal of the fixed appliances.

There are three groups :

1. a group of patient being irradiated with low-level laser therapy (LLLT) at specific time points to relieve pain and discomfort.
2. a group of patient in which pain control will be accomplished by prescribing Panadol Extra tablets in a regular manner.
3. a group of patients in which nothing will be given to them during the course of treatment.

Conditions

  • Pain and Discomfort
  • Orthodontic Appliance Complication

Interventions

RADIATION

low-level laser therapy

low-level laser therapy will be used to relieve pain and discomfort during orthodontic treatment at specific time points.

DRUG

Panadol-extra

Tablets of 565-mg Panadol-extra will be used at specific time points to control pain and discomfort

Sponsors & Collaborators

  • Damascus University

    lead OTHER

Principal Investigators

  • Amer M Owayda, DDS · MSc student in Orthodontics, University of Damascus Dental School, Damascus, Syria

  • Mohammad Y Hajeer, DDS MSc PhD · Associate Professor of Orthodontics, Department of Orthodontics, University of Damascus Dental School, Damascus, Syria

  • Rashad T Murad, DDS MSc PhD · Associate Professor of Toxins and Pharmaceutics , Faculty of Pharmacology, University of Damascus, Damascus, Syria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-15
Primary Completion
2019-03-15
Completion
2019-07-01

Countries

  • Syria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03400111 on ClinicalTrials.gov